Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Baxter
Colorcon
Mallinckrodt
Medtronic

Last Updated: December 13, 2019

DrugPatentWatch Database Preview

Litigation Details for Tabaian v. Intel Corporation (D. Or. 2018)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Tabaian v. Intel Corporation (D. Or. 2018)

Docket   Start Trial Date Filed 2018-02-21
Court District Court, D. Oregon Date Terminated
Cause 35:271 Patent Infringement Assigned To Marco Antonio Hernandez
Jury Demand Both Referred To
Parties AHMAD ASHRAFZADEH; FEREYDUN TABAIAN; INTEL CORPORATION
Patents 10,029,011; 10,029,015; 10,041,044; 10,066,019; 10,086,011; 10,099,019; 5,010,010; 6,002,008; 6,005,020; 7,078,020; 8,067,025; 9,022,022; 9,023,001; 9,109,010
Attorneys Anna Marie Joyce; Arthur W. Coviello; Grant K. Rowan; Howard L. Close; J. Andrew Love; James DeRouin; James E. Geringer; Jeffrey Stewart Love; John D. Vandenberg; Jordan L. Hirsch; Kathleen S. Rose; Luke Motley , IV; Mark W. Wilson; Michael J. Summersgill; Patrick B. McAndrew; Renee E. Rothauge; Richard N. Laminack; Ronald L. Flack , Jr.; Ryan J. McBrayer; Sarah J. Crooks; Todd C. Zubler
Firms Laminack, Pirtle & Martines; Law Offices of Luke Motley, IV PC; Markowitz Herbold PC; Perkins Coie LLP; Perkins Coie, LLP (Seattle); Wilmer Cutler Pickering Hale & Dorr LLP; Wilmer Cutler Pickering Hale and Dorr LLP; Wilmer, Cutler, Pickering, Hale & Dorr, LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Tabaian v. Intel Corporation
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Tabaian v. Intel Corporation

Details for Tabaian v. Intel Corporation (D. Or. 2018)

Date Filed Document No. Description Snippet Link To Document
2019-03-26 126 17:7, 18:20, 25:23, 23:22, 28:2, 28:10, 29:11, 7:3, 9:21, 9:22, 10:23, creating… claim's calibration control circuit of the patent 16 can be six different combinations of 11… limitations that are 16 required by their patent. And then each of their separate 17 … how and to allege how these infringe on the patent. 3 Number two, some of the infringement…points. I'm one 24 of the patent attorneys, and I can maybe address that in a 25 External link to document
2019-05-13 152 input and the load voltage input. ’944 patent, claim 9 (10:41-44) (“The circuit of claim 1 where said nonvolatile…implements the droop function. ’944 patent, 8:64-67. And since the patent is clear that the droop outputs…adjust voltage. But that is not what the patent says. The patent explains that the droop outputs adjust…which the patent says allows droop settings to be adjusted after manufacturing. ’944 patent, 5:18-21 (… question is how the ’944 patent describes “droop outputs,” and the patent is unequivocal that droop External link to document
2019-07-15 161 42:17, 44:17, 76:15 OHM [1] - 12:5 66:10, 66:19, 66:24, 67:8, 68:1, 73:9, namely [1] - 45…title of the patent, the '944 patent, in the abstract, and 5 throughout the patent itself. …in the '944 patent. I'm showing the 25 abstract and title of the patent on this page. …that you're going to see in the patent, in the 7 '944 patent, is the term "droop," …of the patent at issue 15 in this case, which we'll refer to as the '955 [sic] patent. 16 External link to document
2019-07-15 162 7:6, 7:7, 7:13, columns [1] - 100:1 29:10, 29:15, 29:17, 29:23, 29:24, 7:15, 7:17, 7:20… 6 1 come to the patent attorneys. And the patent attorney's job 2 is to sort…minutiae of patent law about how you go about drafting the 11 claims. And the minutiae of patent law relates…applicants submitted with their patent 14 application. And the Patent Office said that, well, some… 13 which is a typical patent application that results in a 14 patent -- must show every feature External link to document
2018-07-17 55 Transcript of Proceedings 13:5, 14:3, 28:8, 26:17, 29:16, 30:10, 29:15 30:21, 31:1 understandable …right that your patent covers that, then you 12 cover the prior art and the patent is invalid."…why, you know, in these local patent rules 14 and in typical patent cases, when you have contentions…Western Washington's local 5 rules regarding patent. 6 Are both sides asking that …given case, and that's one of the reasons why patent 23 local rules have not been adopted. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
McKesson
Medtronic
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.